Effects of Calcium Channel Blockers on Glucose Tolerance in Hypertensive Patients
Author Information
Author(s): Fukao Kosuke, Shimada Kazunori, Hiki Makoto, Kiyanagi Takashi, Hirose Kuniaki, Kume Atsumi, Ohsaka Hiromichi, Matsumori Rie, Kurata Takeshi, Miyazaki Tetsuro, Daida Hiroyuki
Primary Institution: Juntendo University School of Medicine
Hypothesis
Azelnidipine administration could improve glucose tolerance and insulin levels in non-diabetic patients with essential hypertension.
Conclusion
Azelnidipine treatment may have beneficial effects on glucose tolerance, insulin sensitivity, the inflammatory state, and the number of circulating progenitor cells in non-diabetic patients with essential hypertension.
Supporting Evidence
- Azelnidipine significantly decreased glucose and insulin levels 120 minutes after the oral glucose tolerance test compared to amlodipine.
- The heart rate significantly decreased after azelnidipine administration compared to amlodipine.
- Circulating hematopoietic progenitor cells were significantly increased after azelnidipine treatment.
Takeaway
This study found that a medication called azelnidipine can help people with high blood pressure who don't have diabetes by improving how their body handles sugar.
Methodology
Seventeen non-diabetic patients with essential hypertension were enrolled in a crossover study where they received either azelnidipine or amlodipine for 12 weeks, with glucose tolerance tests and blood samples taken at baseline and after each treatment.
Limitations
The sample size was small, and the study only assessed the effects over 12 weeks.
Participant Demographics
11 men and 6 women, mean age 56 years.
Statistical Information
P-Value
P < 0.005 for heart rate, P = 0.039 for glucose levels, P = 0.026 for insulin levels.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website